BioSpace News Archive

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Moberg Pharma AB announces that it has received approval of the pediatric plan for MOB-015 from EMA’s paediatric committee.

SINGAPORE patients with an aggressive form of lung cancer can now access a new therapy that may improve outcomes.

Vicore Pharma Holding AB, a rare disease pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis, announced it will host a key opinion leader webinar on C21, the company’s lead asset for the treatment of idiopathic pulmonary fibrosis on Thursday, September 30, 2021 at 16:00 CET.

ITM, a leading radiopharmaceutical biotech company, announced with the registration in the Commercial Register of the District Court of Munich, the completion of its conversion from a German stock corporation into a European company.

Enlivex Therapeutics Ltd. announced the initiation of dosing in its multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome.

Corvus Pharmaceuticals, Inc. provided an update on its development programs in oncology and infectious disease for mupadolimab, a humanized monoclonal antibody directed against CD73 with a proposed dual mechanism of activating B cells to generate immune responses to viruses and tumor antigens, and inhibiting the production of immunosuppressive adenosine in the tumor micro environment.

Samsung Biologics, a global contract development and manufacturing organization, introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.

Xenikos B.V. today announced the appointment of Hassan Aly, MD, PhD, as Chief Medical Officer.